Mehta Roopa, Zubirán Rafael, Martagón Alexandro J, Vazquez-Cárdenas Alejandra, Segura-Kato Yayoi, Tusié-Luna María Teresa, Aguilar-Salinas Carlos A
Departamento de Endocrinologia y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey, Mexico.
J Lipid Res. 2016 Dec;57(12):2115-2129. doi: 10.1194/jlr.R072231. Epub 2016 Oct 24.
The burden caused by familial hypercholesterolemia (FH) varies among countries and ethnic groups. The prevalence and characteristics of FH in Latin American (LA) countries is largely unknown. We present a systematic review (following the PRISMA statement) of FH in LA countries. The epidemiology, genetics, screening, management, and unique challenges encountered in these countries are discussed. Published reports discussing FH in Hispanic or LA groups was considered for analysis. Thirty studies were included representing 10 countries. The bulk of the data was generated in Brazil and Mexico. Few countries have registries and there was little commonality in FH mutations between LA countries. LDL receptor mutations predominate; APOB and PCSK9 mutations are rare. No mutation was found in an FH gene in nearly 50% of cases. In addition, some country-specific mutations have been reported. Scant information exists regarding models of care, cascade screening, cost, treatment effectiveness, morbidity, and mortality. In conclusion, FH is largely underdiagnosed and undertreated in the LA region. The genetic admixture with indigenous populations, producing mestizo's groups, may influence the mutational findings in Latin America. Potential opportunities to close gaps in knowledge and health care are identified.
家族性高胆固醇血症(FH)所造成的负担在不同国家和种族群体中有所不同。拉丁美洲(LA)国家中FH的患病率和特征在很大程度上尚不明确。我们对LA国家的FH进行了一项系统综述(遵循PRISMA声明)。讨论了这些国家中FH的流行病学、遗传学、筛查、管理以及所面临的独特挑战。纳入分析的是讨论西班牙裔或LA群体中FH的已发表报告。共纳入了代表10个国家的30项研究。大部分数据来自巴西和墨西哥。很少有国家建立了登记系统,而且LA国家之间FH突变几乎没有共性。低密度脂蛋白受体突变占主导;载脂蛋白B(APOB)和前蛋白转化酶枯草溶菌素9(PCSK9)突变罕见。近50%的病例在FH基因中未发现突变。此外,还报告了一些特定国家的突变情况。关于照护模式、级联筛查、成本、治疗效果、发病率和死亡率的信息匮乏。总之,FH在LA地区大多未得到充分诊断和治疗。与原住民的基因混合产生了混血群体,这可能会影响拉丁美洲的突变研究结果。确定了缩小知识和医疗保健差距的潜在机会。